Product Description
Buspirone is used to treat anxiety disorders or in the short-term treatment of symptoms of anxiety. Buspirone is in a class of medications called anxiolytics. It works by changing the amounts of certain natural substances in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a688005.html)
Mechanisms of Action: 5-HT1A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Brazil | Canada | Chile | China | Colombia | Czech | Denmark | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Malta | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | South Africa | Sri Lanka | Sweden | Taiwan | Turkey | Ukraine | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Emotional Brain
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Russia
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Dizziness|Generalized anxiety disorder|Myocardial Infarction|Primary Dysautonomias|Vertigo
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BGFN-2022-01 | P3 |
Recruiting |
Generalized anxiety disorder |
2026-06-30 |
|
| BUSP-03-03-2021 | P3 |
Completed |
Dizziness|Vertigo|Primary Dysautonomias |
2022-05-09 |
48% |
| 2019-002182-35 | P3 |
Active, not recruiting |
Unknown |
2022-01-10 |
|
| COOL AMI EU PIVOTAL TRIAL | P3 |
Active, not recruiting |
Myocardial Infarction |
None |